Paxlovid-like nirmatrelvir/ritonavir fails to block SARS-CoV-2 transmission in ferrets

• Published in: bioRxiv
• Main Authors: Cox, Robert, Lieber, Carolin M, Wolf, Josef D, Karimi, Amirhossein, Nicole Ap Lieberman, Sticher, Zachary M, Roychoudhury, Pavitra, Andrews, Meghan K, Krueger, Rebecca E, Natchus, Michael G, Painter, George R, Kolykhalov, Alexander, Greninger, Alexander L, Plemper, Richard K
• Format: Paper Journal Article
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 21.11.2022; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: Animal models; Antiviral agents; Clinical trials; Controlled conditions; COVID-19; Disease transmission; Drug dosages; Microbiology; Mustela; Older people; Oral administration; Patients; Pharmaceuticals; Pharmacokinetics; Respiratory tract diseases; Risk groups; Ritonavir; Severe acute respiratory syndrome coronavirus 2

Despite the continued spread of SARS-CoV-2 and emergence of variants of concern (VOC) that are capable of escaping preexisting immunity, therapeutic options are underutilized. In addition to preventing severe disease in high-risk patients, antivirals may contribute to interrupting transmission chain...